Aleafia Health Inc. (TSX:AH) (OTCQX:ALEAF) has repaid a $25 million debt to Emblem Corp. in cash.
Emblem Corp. issued an 8% unsecured convertible debt on Feb. 2, 2018. The Toronto-based company acquired it on March 14, 2019.
“Our team is excited to see continued cannabis sales growth in 2021, driven by new products launched late last year,” said Aleafia Health CEO Geoffrey Benic.
“The adult-use, medical and international cannabis markets are the pillars of our 2021 growth strategy, and we look forward to capitalizing on this global opportunity through the continued expansion of our cannabis product portfolio,” Benic added.
The fourth quarter was Aleafia s best quarter to date for cannabis sales. Over the last month, the vertically integrated cannabis company boosted its global distribution network by agreeing to supply Europe-based pharmaceutical producer and distributor Apipharm Veletrgovina d.o.o. with cannabis flower under the three-year agreement.
#3 This Is A Big Data Coup
Cannabis data is the difference between a successful market and a
very successful market.
It’s the only thing connecting medical cannabis to medical science …
It’s the missing element that could cut millions of dollars off the costs of getting new cannabis based pharmaceutical drugs approved …
That also means it’s one thing that will attract the lucrative attention of Big Pharma.
It’s also one thing Juva has brought to the table.
And when the company went public in November, it heralded a business plan of creating a potential lucrative nexus between medical cannabis and big pharma.
Cutting-edge life science company offers high upside cannabis medical product potential. The company aims to disrupt the drug development market by developing evidence-based cannabis products to help combat serious medical conditions